Cardiol Therapeutics (CRDL)
(Real Time Quote from BATS)
$2.06 USD
+0.05 (2.49%)
Updated May 1, 2024 03:44 PM ET
After-Market: $2.06 0.00 (0.00%) 4:06 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Cardiol Therapeutics Inc. (CRDL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.50 | $9.00 | $4.50 | 223.38% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Cardiol Therapeutics Inc. comes to $6.50. The forecasts range from a low of $4.50 to a high of $9.00. The average price target represents an increase of 223.38% from the last closing price of $2.01.
Analyst Price Targets (3 )
Broker Rating
Cardiol Therapeutics Inc. currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on two recommendations.
Of the three recommendations deriving the current ABR, two are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 66.67% and 33.33% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 50%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 1 | 1 | 1 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/22/2024 | H.C. Wainwright & Co. | Vernon Bernardino | Not Available | Strong Buy |
3/25/2024 | Leede Jones Gable | Douglas W Loe | Moderate Buy | Moderate Buy |
3/15/2024 | Canaccord Genuity | Edward H Nash | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 3 |
Average Target Price | $6.50 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 99 of 252 |
Current Quarter EPS Est: | -0.06 |